1888PressRelease.com
1888 PressRelease Home Sign In Register About Us Sitemap
  
02
Oct
2009

Avodart (dutasteride) Regulatory Update

GlaxoSmithKline (GSK) announced today that it has filed a supplemental New Drug Application (sNDA) for Avodart® (dutasteride) with the US Food and Drug Administration (FDA) for prostate cancer risk reduction among men at increased risk of developing the disease.


(1888PressRelease) October 02, 2009 - EU filings also are underway via the European Mutual Recognition Variation Procedure, with Sweden acting as the Reference Member State.

Dutasteride is not approved or licensed anywhere in the world to treat or reduce the risk of prostate cancer. For more information about Avodart, please see the full prescribing information at www.gsk.com.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

For further information please visit www.gsk.com

Enquiries:

UK Media enquiries:
Philip Thomson
(020) 8047 5502

###
 

Other Related Press Releases

Xlibris Launches Podcast Marketing Service for Self Published Authors by Xlibris Corporation

DOCOMO, NEC, Panasonic Mobile Communications, Fujitsu Push Ahead with LTE Mobile-Terminal Platform - Complete development of LTE-PF chipset engineering sample by Financial News

Studio 355 Hair & Day Spa hires #1 Hair Stylist for Businessmen in Maryland by Vincent Roa Group, Llc

Avodart (dutasteride) Regulatory Update by Economic News

Tata Motors September sales at 52,513 nos., growth of 6% by Business Updates

Arbitron Announces Cross-Platform Media Measurement Group by Financial News

Contact Information

Philip Thomson

Economic News

Voice: (020) 8047 5502

Visit our Site

Press Release Tools